RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA
Clinical trials for RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA explained in plain language.
Never miss a new study
Get alerted when new RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA trials appear
Sign up with your email to follow new studies for RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Gene therapy heals wounds in rare skin disease?
Disease control OngoingThis phase 3 trial tests a gene therapy called FCX-007 for people with recessive dystrophic epidermolysis bullosa, a rare disease that causes fragile skin and painful blisters. The therapy uses the patient's own skin cells, genetically corrected to produce collagen, and injects t…
Matched conditions: RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA
Phase: PHASE3 • Sponsor: Castle Creek Biosciences, LLC. • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Stem cell therapy offers hope for children with butterfly skin
Disease control OngoingThis study tests a stem cell treatment for epidermolysis bullosa, a rare disease causing fragile skin that blisters easily. About 91 people with two types of EB will receive the cells or a placebo through an IV. The main goal is to see if the treatment can safely close stubborn w…
Matched conditions: RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA
Phase: PHASE3 • Sponsor: RHEACELL GmbH & Co. KG • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Stem cell trial aims to heal wounds in 'Butterfly Skin' disease
Disease control OngoingThis phase 3 trial tests whether ABCB5-positive stem cells given through an IV can safely and effectively heal wounds in people with epidermolysis bullosa, a rare genetic condition that causes fragile, blistering skin. The study includes 9 participants with a specific type of the…
Matched conditions: RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA
Phase: PHASE3 • Sponsor: RHEACELL GmbH & Co. KG • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
AI app aims to catch deadly skin cancer early in rare disease patients
Diagnosis OngoingThis study is developing an artificial intelligence app to detect squamous cell carcinoma (a type of skin cancer) in people with recessive dystrophic epidermolysis bullosa (RDEB), a rare genetic blistering condition. Twenty adults with RDEB and a history of skin cancer will submi…
Matched conditions: RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA
Sponsor: Northwestern University • Aim: Diagnosis
Last updated Jun 27, 2026 09:01 UTC
-
New eye drops aim to soothe blistering eye pain in rare skin disease
Symptom relief OngoingThis early-stage study tests whether ELK-003 eye drops can safely reduce eye symptoms in people with two types of epidermolysis bullosa (EB), a rare condition causing fragile skin and blisters. About 20 participants will first be observed without treatment, then receive the eye d…
Matched conditions: RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA
Phase: PHASE1 • Sponsor: Fundación DEBRA Chile, Niños Piel de Cristal • Aim: Symptom relief
Last updated Jun 27, 2026 08:07 UTC